



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7


[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

## SDU-071

|                    |  |
|--------------------|--|
| Cat. No.:          | HY-162352  |
| Molecular Formula: | C <sub>28</sub> H <sub>25</sub> N <sub>3</sub> O <sub>2</sub>  |
| Molecular Weight:  | 435.52   |
| Target:            | Epigenetic Reader Domain; Apoptosis  |
| Pathway:           | Epigenetics; Apoptosis   |
| Storage:           | -20°C, protect from light, stored under nitrogen<br>* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen) |



### SOLVENT & SOLUBILITY

|   |  |                          |           |            |            |
|---|--|--------------------------|-----------|------------|------------|
| In Vitro  | DMSO : 100 mg/mL (229.61 mM; Need ultrasonic)  |                          |           |            |            |
|   |  | Solvent<br>Concentration | Mass      |            |            |
|   | Preparing Stock Solutions  |                          | 1 mg      | 5 mg       | 10 mg      |
|   |  | 1 mM                     | 2.2961 mL | 11.4805 mL | 22.9611 mL |
|   |  | 5 mM                     | 0.4592 mL | 2.2961 mL  | 4.5922 mL  |
|   | 10 mM  | 0.2296 mL                | 1.1481 mL | 2.2961 mL  |            |
| Please refer to the solubility information to select the appropriate solvent. |  |                          |           |            |            |
| In Vivo   | 1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline<br>Solubility: ≥ 4 mg/mL (9.18 mM); Clear solution |                          |           |            |            |

### BIOLOGICAL ACTIVITY

|             |  |                   |  |
|-------------|--|-------------------|--|
| Description | SDU-071 is a potent and orally active inhibitor of BRD4-p53 inhibitor. SDU-071 inhibits MDA-MB-231 cells proliferation with an IC <sub>50</sub> of 10.5 μM. SDU-071 induces cell cycle arrest and apoptosis <sup>[1]</sup> . |                   |  |
| In Vitro    | SDU-071 (10 μM, 24 h) induces cell-cycle arrest and apoptosis in MDA-MB-231 cells <sup>[1]</sup> .   |                   |  |
|             | SDU-071 (10 μM, 72 h) inhibits cell proliferation, migration, and invasion in MDA-MB-231 cells <sup>[1]</sup> .  |                   |  |
|             | MCE has not independently confirmed the accuracy of these methods. They are for reference only.  |                   |  |
|             | Apoptosis Analysis <sup>[1]</sup>  |                   |  |
|             | Cell Line:   | MDA-MB-231cells   |  |
|             | Concentration:   | 2.5, 5, and 10 μM |  |
|             | Incubation Time:   | 24 hours          |  |

|                 |   |               |   |         |  |                 |                              |         |   |
|-----------------|---|---------------|---|---------|--|-----------------|------------------------------|---------|---|
|                 | <table border="1"> <tr> <td>Result:</td> <td>Altered cell cycle progression in the G1, S, and G2/M phases.<br/>Induced apoptosis in MDA-MB-231 cells.</td> </tr> </table>   | Result:       | Altered cell cycle progression in the G1, S, and G2/M phases.<br>Induced apoptosis in MDA-MB-231 cells. |         |  |                 |                              |         |   |
| Result:         | Altered cell cycle progression in the G1, S, and G2/M phases.<br>Induced apoptosis in MDA-MB-231 cells.   |               |   |         |  |                 |                              |         |   |
| <b>In Vivo</b>  | <p>SDU-071 (250 mg/kg for i.g; once daily for 21 days) inhibits tumor growth in a MDA-MB-231 orthotopic mouse xenograft mammary tumor model<sup>[1]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>DA-MB-231 Orthotopic Mouse Xenograft Mammary Tumor Model<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>50 and 250 mg/kg; Once daily for 21 days</td> </tr> <tr> <td>Administration:</td> <td>Gavage administration (i.g.)</td> </tr> <tr> <td>Result:</td> <td>Significantly inhibited tumor growth with 49.1% inhibition.<br/>Reduced the Protein levels for BRD4, Mucin5AC, c-Myc, CDK4, and CDK6, upregulated the p21 protein.</td> </tr> </table> | Animal Model: | DA-MB-231 Orthotopic Mouse Xenograft Mammary Tumor Model <sup>[1]</sup>                                 | Dosage: | 50 and 250 mg/kg; Once daily for 21 days | Administration: | Gavage administration (i.g.) | Result: | Significantly inhibited tumor growth with 49.1% inhibition.<br>Reduced the Protein levels for BRD4, Mucin5AC, c-Myc, CDK4, and CDK6, upregulated the p21 protein. |
| Animal Model:   | DA-MB-231 Orthotopic Mouse Xenograft Mammary Tumor Model <sup>[1]</sup>   |               |   |         |  |                 |                              |         |   |
| Dosage:         | 50 and 250 mg/kg; Once daily for 21 days  |               |   |         |  |                 |                              |         |   |
| Administration: | Gavage administration (i.g.)  |               |   |         |  |                 |                              |         |   |
| Result:         | Significantly inhibited tumor growth with 49.1% inhibition.<br>Reduced the Protein levels for BRD4, Mucin5AC, c-Myc, CDK4, and CDK6, upregulated the p21 protein.   |               |   |         |  |                 |                              |         |   |

## REFERENCES

[1]. Wang S, et al. Novel BRD4-p53 Inhibitor SDU-071 Suppresses Proliferation and Migration of MDA-MB-231 Triple-Negative Breast Cancer Cells[J]. ACS Pharmacology & Translational Science, 2024.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA